All In Biotech

Drug Trial Radar · NCT01431820

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study

Last checked: Nov 20, 2026Latest source record: Nov 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 334 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

334

Actual

Start

May 2012

Primary completion

Jun 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Topica PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 12, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of a topical antifungal formulation, Luliconazole Solution, 10%, in the treatment of adults with onychomycosis of the toenails.

Conditions

  • Distal and Lateral Subungual Onychomycosis

Interventions

  • Luliconazole Solution, 10%Drug

    Topical

  • Vehicle SolutionDrug

    Topical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects who achieve complete cure of the target great toenailTime frame: Week 52

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Denver, Colorado

  • Site not named

    Aventura, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Boise, Idaho

  • Site not named

    Evansville, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Detroit, Michigan

  • Site not named

    Fridley, Minnesota

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    East Setauket, New York

  • Site not named

    Rochester, New York

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Portland, Oregon

  • Site not named

    Knoxville, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    College Station, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Lynchburg, Virginia

  • Site not named

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.